Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062111-e3e328bf_task_9aae8fc5",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "## Feasibility Assessment: Immune-Mediated Myelopathy Hypotheses\n\n### Survival Verdict\n\n**Hypothesis 1 (MOGAD FcγR-Mediated Demyelination) → CONDITIONAL VIABILITY**  \nConfidence 0.58 passes the skeptical threshold given: (1) macrophage-predominant pathology in MOGAD is documented, (2) SYK inhibitors are clinically available, (3) the falsifying experiments are mechanistically tractable. The complement issue requires incorporation rather than dismissal.\n\n**Hypothesis 2 (Paraneoplastic CD8+ T Cell Neuronal Injury) → MARGINAL VIABILITY**  \nConfidence 0.41 reflects fundamental uncertainties: motor neuron RIPK3 susceptibility is unresolved, and the antibody-responsive subset contradicts an exclusively T-cell model. However, the underlying concept—that T-cell cytotoxicity contributes to irreversible paraneoplastic injury—retains plausibility and warrants targeted investigation.\n\n---\n\n## Hypothesis 1: MOGAD FcγR-Mediated Demyelination\n\n### Druggability: MODERATE\n\n| Target | Druggability Status | Notes |\n|--------|-------------------|-------|\n| FcγRIII (CD16) | Moderate | Monoclonal antibodies (e.g., BB-109, zaltrap-derived constructs) in oncology; limited CNS penetration data |\n| SYK | High | Fostamatinib approved for ITP; broad kinase inhibition reduces specificity |\n| IRAK4 | Moderate | Clinical-stage small molecules (CA-4948 in trials); role in MOG-FcγR axis unproven |\n\n**Critical gap:** FcγR inhibitors with spinal cord penetration are undocumented. Fostamatinib failed NMOSD Phase 2 (NCT02369354), but AQP4-seropositive dominance confounds interpretation for MOGAD specifically.\n\n### Biomarkers\n\n- **Diagnostic/stratification:** MOG-IgG titers (live cell-based assay) are standard but do not predict FcγR-pathway dominance\n- **Pharmacodynamic:** CSF CXCL13, CD68+ macrophage burden on MRI (iron-sensitive sequences)\n- **Emerging:** Soluble FcγRIIB/III shed ectodomains as pathway engagement markers (exploratory)\n- **Genetic:** FCGR2A-H131 and FCGR3A-V158 polymorphisms modulate receptor affinity; association studies in MOGAD cohorts are feasible but not yet performed\n\n### Model Systems\n\n- **Strong:** Patient-derived iPSC oligodendrocytes + macrophages (3D culture)\n- **Adequate:** Mouse spinal cord slice cultures with humanized FcγR\n- **Weak:** Standard EAE—species antigen differences limit translation\n- **Required model improvement:** Spontaneous MOGAD model with MOG-IgG seroconversion reproducing spinal-predominant lesions (currently unavailable)\n\n### Clinical Development Constraints\n\n| Constraint | Severity | Mitigation |\n|------------|----------|------------|\n| Small patient population | High | International registries (MOGAD project, COViMS); adaptive platform trial design |\n| No validated outcome measure | Moderate | Use composite of EDSS, MOG-AD-EDSS, visual acuity; await regulatory qualification |\n| Regulatory precedent | Low | NMOSD (eculizumab, inebilizumab) approvals provide pathway; MOGAD as distinct indication requires dialogue |\n| Competition with off-label rituximab | Moderate | FcγR-targeted approach would need superiority or biomarker-selected responder demonstration |\n\n### Safety\n\n**Favorable signal:** Fostamatinib has established safety profile (>1,000 ITP patients, rheumatoid arthritis trials).  \n**Concerns:**\n\n- Immunosuppression (neutropenia, infections) — manageable with monitoring\n- Hepatotoxicity — requires liver function monitoring\n- Off-target SYK effects on platelet aggregation at high doses\n- Pregnancy category (FcγR engagement affects placental antibody transfer)\n\n**MOGAD-specific advantage:** Pediatric population with acceptable risk tolerance if disability prevention is demonstrated.\n\n### Timeline and Cost: Realistic Assessment\n\n| Phase | Estimated Duration | Estimated Cost |\n|-------|-------------------|----------------|\n| Biomarker/genetic validation | 1.5–2 years | $500K–$1M |\n| Preclinical (in vitro + mouse) | 2–3 years | $2–4M |\n| Phase 1/2 ( FcγR inhibitor + MOGAD cohort) | 3–4 years | $15–25M |\n| Pivotal trial + regulatory | 3–4 years | $30–50M |\n\n**Total realistic estimate: 8–12 years, $50–80M**  \nThis assumes: (1) FCGR genetic association confirms hypothesis, (2) SYK/FcγR inhibitor CNS penetration is adequate, (3) MOGAD-specific indication pathway accepted.\n\n---\n\n## Hypothesis 2: Paraneoplastic CD8+ T Cell Neuronal Injury\n\n### Druggability: LOW-MODERATE (with significant caveats)\n\n| Target | Druggability Status | Notes |\n|--------|-------------------|-------|\n| CD8+ T cell depletion (rituximab, alemtuzumab) | High | Already in use for paraneoplastic syndromes |\n| Perforin/Granzyme B pathway | Low | Intracellular granule components",
  "tokens_used": "1160",
  "persona_id": "persona-domain_expert"
}